Summary

The rate of mortality after cardiogenic shock remains high. However, mortality is not reduced with the currently available devices that provide hemodynamic support. The benefit with inotropic drug therapy is also limited. As the technology evolves, it is anticipated the management of cardiogenic shock will improve, but better identification of patients to benefit is needed.